Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 5/20 | 0.60 |
| ▸ | SLC22A12 | Q96S37 | 14/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.54 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.54 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1472100 | 0.82 | PGR (0.71) | AXLNR3C1PGRARESR2 | |
| SCHEMBL5290647 | 0.81 | KMT2A (0.53) | AXLNR3C1PGRARESR2 | |
| SCHEMBL1474002 | 0.79 | PGR (0.60) | NR3C1PGRARESR2 | |
| SCHEMBL1471955 | 0.78 | LMNA (0.73) | AXLSLC22A12CYP2C9SLC22A6SLC22A8 | |
| SCHEMBL1592159 | 0.75 | AXL (1.00) | AXL | |
| SCHEMBL31411241 | 0.74 | NPC1 (0.56) | CYP2C9 | |
| SCHEMBL19154982 | 0.74 | NPC1 (0.56) | CYP2C9 | |
| SCHEMBL3769130 | 0.72 | SLC22A12 (0.70) | SLC22A12CYP2C9SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL95728 | 0.70 | SLC22A12 (0.68) | SLC22A12CYP2C9SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL29118842 | 0.70 | SLC22A12 (0.68) | SLC22A12CYP2C9SLC22A6SLC22A8SLC22A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651595-A2 | UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005007621-A2 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | claimed |
| US-20050009871-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | claimed |
| US-7915293-B2 | Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915293-B2 | Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915293-B2 | Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| WO-2005007621-A2 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050009871-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009871-A1 | Ubiquitin ligase inhibitors | NEDD4, STUB1, UBE3A | AXL 3086/4885SLC22A12 4627/4885CYP2C9 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.